- Home
- PTGX vs FOLD Comparison
PTGX vs FOLD Comparison
Compare PTGX & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTGX | FOLD |
|---|---|---|
| Founded | 2006 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.5B |
| IPO Year | 2016 | 2006 |
Fundamental Metrics
Financial Performance| Metric | PTGX | FOLD |
|---|---|---|
| Price | $92.39 | $14.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $100.17 | $27.25 |
| AVG Volume (30 Days) | 489.3K | ★ 3.6M |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $711.26 | $20.50 |
| Revenue Next Year | N/A | $18.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.60 | $5.66 |
| 52 Week High | $96.54 | $14.38 |
Technical Indicators
Market Signals| Indicator | PTGX | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 60.15 | 66.13 |
| Support Level | $76.63 | $14.21 |
| Resistance Level | $92.05 | $14.37 |
| Average True Range (ATR) | 3.87 | 0.03 |
| MACD | 0.79 | -0.04 |
| Stochastic Oscillator | 80.77 | 42.86 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.